Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death

Lidong Zhang, Hongbo Zhu, John J. Davis, Dietmar Jacob, Shuhong Wu, Fuminori Teranishi, Angelica Gutierrez, Yibin Wang, Bingliang Fang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Activation of MAP kinases is involved in various cellular processes, including immunoregulation, inflammation, cell growth, cell differentiation, and cell death. To investigate the role of p38 MAP kinase activation in the signaling pathway of TRAIL-mediated apoptosis, we compared TRAIL-mediated MAP kinase activation in TRAIL-susceptible human colon cancer cell line DLD1 and TRAIL-resistant DLD1/TRAIL-R cells. TRAIL-mediated activation of ERK occurred in both cell lines. In contrast, both DLD1 and DLD1/TRAIL-R cells showed no obvious JNK activation after treatment with TRAIL. Interestingly, TRAIL-mediated activation of p38 MAP kinases was observed in DLD1 cells but not in DLD1/TRAIL-R cells. However, activation of p38 MAP kinases was observed in both DLD1 and DLD1/TRAIL-R cells after treatment with anisomycin. Furthermore, inhibiting activated p38 MAP kinases with known inhibitors or with an adenovector expressing dominant negative p38α did not block TRAIL-mediated cell death in DLD1 cells. Moreover, activation of p38 MAP kinases by adenovectors expressing constitutive MKK3 or MKK6 (Ad/MKK3bE or Ad/MKK6bE) did not induce cell death in either DLD1 or DLD1/TRAIL-R cell lines. Our results suggest that activation of p38 MAP kinases does not play a major role in TRAIL-mediated apoptosis in DLD1 cells and that lack of TRAIL-mediated p38 MAP kinase activation may not be the mechanism of TRAIL-resistance in DLD1/TRAIL-R cells.

Original languageEnglish
Pages (from-to)296-301
Number of pages6
JournalCancer Biology and Therapy
Volume3
Issue number3
DOIs
Publication statusPublished - Jan 1 2004
Externally publishedYes

Fingerprint

p38 Mitogen-Activated Protein Kinases
Cell Death
Cell Line
Phosphotransferases
Anisomycin
Apoptosis
Colonic Neoplasms
Cell Differentiation
Inflammation
Growth

Keywords

  • Apoptosis
  • Cancer
  • p38 MAP kinases
  • Resistance
  • TRAIL

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. / Zhang, Lidong; Zhu, Hongbo; Davis, John J.; Jacob, Dietmar; Wu, Shuhong; Teranishi, Fuminori; Gutierrez, Angelica; Wang, Yibin; Fang, Bingliang.

In: Cancer Biology and Therapy, Vol. 3, No. 3, 01.01.2004, p. 296-301.

Research output: Contribution to journalArticle

Zhang, Lidong ; Zhu, Hongbo ; Davis, John J. ; Jacob, Dietmar ; Wu, Shuhong ; Teranishi, Fuminori ; Gutierrez, Angelica ; Wang, Yibin ; Fang, Bingliang. / Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. In: Cancer Biology and Therapy. 2004 ; Vol. 3, No. 3. pp. 296-301.
@article{d24b8462f5e84cfdb2c3cb50b7a77e1c,
title = "Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death",
abstract = "Activation of MAP kinases is involved in various cellular processes, including immunoregulation, inflammation, cell growth, cell differentiation, and cell death. To investigate the role of p38 MAP kinase activation in the signaling pathway of TRAIL-mediated apoptosis, we compared TRAIL-mediated MAP kinase activation in TRAIL-susceptible human colon cancer cell line DLD1 and TRAIL-resistant DLD1/TRAIL-R cells. TRAIL-mediated activation of ERK occurred in both cell lines. In contrast, both DLD1 and DLD1/TRAIL-R cells showed no obvious JNK activation after treatment with TRAIL. Interestingly, TRAIL-mediated activation of p38 MAP kinases was observed in DLD1 cells but not in DLD1/TRAIL-R cells. However, activation of p38 MAP kinases was observed in both DLD1 and DLD1/TRAIL-R cells after treatment with anisomycin. Furthermore, inhibiting activated p38 MAP kinases with known inhibitors or with an adenovector expressing dominant negative p38α did not block TRAIL-mediated cell death in DLD1 cells. Moreover, activation of p38 MAP kinases by adenovectors expressing constitutive MKK3 or MKK6 (Ad/MKK3bE or Ad/MKK6bE) did not induce cell death in either DLD1 or DLD1/TRAIL-R cell lines. Our results suggest that activation of p38 MAP kinases does not play a major role in TRAIL-mediated apoptosis in DLD1 cells and that lack of TRAIL-mediated p38 MAP kinase activation may not be the mechanism of TRAIL-resistance in DLD1/TRAIL-R cells.",
keywords = "Apoptosis, Cancer, p38 MAP kinases, Resistance, TRAIL",
author = "Lidong Zhang and Hongbo Zhu and Davis, {John J.} and Dietmar Jacob and Shuhong Wu and Fuminori Teranishi and Angelica Gutierrez and Yibin Wang and Bingliang Fang",
year = "2004",
month = "1",
day = "1",
doi = "10.4161/cbt.3.3.696",
language = "English",
volume = "3",
pages = "296--301",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death

AU - Zhang, Lidong

AU - Zhu, Hongbo

AU - Davis, John J.

AU - Jacob, Dietmar

AU - Wu, Shuhong

AU - Teranishi, Fuminori

AU - Gutierrez, Angelica

AU - Wang, Yibin

AU - Fang, Bingliang

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Activation of MAP kinases is involved in various cellular processes, including immunoregulation, inflammation, cell growth, cell differentiation, and cell death. To investigate the role of p38 MAP kinase activation in the signaling pathway of TRAIL-mediated apoptosis, we compared TRAIL-mediated MAP kinase activation in TRAIL-susceptible human colon cancer cell line DLD1 and TRAIL-resistant DLD1/TRAIL-R cells. TRAIL-mediated activation of ERK occurred in both cell lines. In contrast, both DLD1 and DLD1/TRAIL-R cells showed no obvious JNK activation after treatment with TRAIL. Interestingly, TRAIL-mediated activation of p38 MAP kinases was observed in DLD1 cells but not in DLD1/TRAIL-R cells. However, activation of p38 MAP kinases was observed in both DLD1 and DLD1/TRAIL-R cells after treatment with anisomycin. Furthermore, inhibiting activated p38 MAP kinases with known inhibitors or with an adenovector expressing dominant negative p38α did not block TRAIL-mediated cell death in DLD1 cells. Moreover, activation of p38 MAP kinases by adenovectors expressing constitutive MKK3 or MKK6 (Ad/MKK3bE or Ad/MKK6bE) did not induce cell death in either DLD1 or DLD1/TRAIL-R cell lines. Our results suggest that activation of p38 MAP kinases does not play a major role in TRAIL-mediated apoptosis in DLD1 cells and that lack of TRAIL-mediated p38 MAP kinase activation may not be the mechanism of TRAIL-resistance in DLD1/TRAIL-R cells.

AB - Activation of MAP kinases is involved in various cellular processes, including immunoregulation, inflammation, cell growth, cell differentiation, and cell death. To investigate the role of p38 MAP kinase activation in the signaling pathway of TRAIL-mediated apoptosis, we compared TRAIL-mediated MAP kinase activation in TRAIL-susceptible human colon cancer cell line DLD1 and TRAIL-resistant DLD1/TRAIL-R cells. TRAIL-mediated activation of ERK occurred in both cell lines. In contrast, both DLD1 and DLD1/TRAIL-R cells showed no obvious JNK activation after treatment with TRAIL. Interestingly, TRAIL-mediated activation of p38 MAP kinases was observed in DLD1 cells but not in DLD1/TRAIL-R cells. However, activation of p38 MAP kinases was observed in both DLD1 and DLD1/TRAIL-R cells after treatment with anisomycin. Furthermore, inhibiting activated p38 MAP kinases with known inhibitors or with an adenovector expressing dominant negative p38α did not block TRAIL-mediated cell death in DLD1 cells. Moreover, activation of p38 MAP kinases by adenovectors expressing constitutive MKK3 or MKK6 (Ad/MKK3bE or Ad/MKK6bE) did not induce cell death in either DLD1 or DLD1/TRAIL-R cell lines. Our results suggest that activation of p38 MAP kinases does not play a major role in TRAIL-mediated apoptosis in DLD1 cells and that lack of TRAIL-mediated p38 MAP kinase activation may not be the mechanism of TRAIL-resistance in DLD1/TRAIL-R cells.

KW - Apoptosis

KW - Cancer

KW - p38 MAP kinases

KW - Resistance

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=14644420166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644420166&partnerID=8YFLogxK

U2 - 10.4161/cbt.3.3.696

DO - 10.4161/cbt.3.3.696

M3 - Article

C2 - 14749540

AN - SCOPUS:14644420166

VL - 3

SP - 296

EP - 301

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -